New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT04243616
Summary
This study is testing whether adding an immunotherapy drug called cemiplimab to standard chemotherapy before surgery can help shrink tumors more effectively in patients with high-risk breast cancer. It involves 36 women with specific types of breast cancer that have not spread beyond the breast and lymph nodes. The main goal is to see if this combination leads to no detectable cancer remaining at the time of surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.